ByParmita Uniyal, New Delhi Aug 08, 2023 04:23 PM IST Share Via Copy Link The severity of a dengue infection can be higher when people experience a second attack. Know how the disease’s symptoms change in case of reinfection. As dengue cases rise rapidly across many parts of the country and Delhi witnesses a remarkable […]
Novo Nordisk’s semaglutide injection reduced major adverse cardiovascular events by 20% in obese or overweight patients without diabetes, further bolstering the case for more widespread use of the game-changing GLP-1. Novo Nordisk said Tuesday morning that the vast SELECT trial investigating semaglutide hit its primary endpoint: the reduction in major adverse cardiovascular events (MACE), which […]
I am dissapointed! We need it to improve investment decisions, like this: “Novo Nordisk weight loss drug cuts investors stock loss risk by 20%”Why not promote its Impulsivity reduction potential.Reduced cravings = reduction of impulsivity = more long term thinking
Companies Novo Nordisk A/S Follow Aug 8 (Reuters) – Novo Nordisk (NOVOb.CO) said on Tuesday its obesity drug Wegovy reduced the risk of a major cardiovascular event like a stroke by 20% in overweight or obese people with a history of heart disease, exceeding expectations from a key late-stage trial. COMMENTS: PETER WELFORD, EQUITY ANALYST, […]
article American Red Cross Right now, the Red Cross especially needs type O negative, type O positive, type B negative and type A negative blood donors, as well as platelet donors. For those who don’t know their blood type, making a donation is an easy way to find out this important personal health information. The […]
Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely-watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy. The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular […]
By Dominic Chopping Shares in Denmark’s Novo Nordisk rose 16% Tuesday after the company said a five-year study of its obesity drug showed it reduced the risk of major adverse cardiovascular events in overweight or obese adults by 20%. Semaglutide, which is marketed as Wegovy, appeared to have a safe and well-tolerated profile and demonstrated […]
Summary Companies SELECT trial tested medical benefits of Wegovy Results much better than expected Data could help expand Wegovy’s use Novo shares hit record highs COPENHAGEN/LONDON, Aug 8 (Reuters) – Novo Nordisk (NOVOb.CO) said on Tuesday a large late-stage study showed its obesity drug Wegovy had a clear medical benefit, in addition to weight loss, […]
Novo Nordisk’s U.S.-listed stock NVO, +3.04% NOVO.B, +10.35% rose 10% premarket Tuesday, after the company said its obesity treatment semaglutide, marketed as Wegovy, met its main goal in a trial evaluating its ability to reduce cardiovascular events and not just help with weight loss. The Danish company said a 2.4 mg dose of semaglutide reduced […]
In 2019, nearly 12 percent of Black individuals experienced pre-term births compared with 7 percent of White individuals, according to a new demography paper. Pre-pregnancy cardiovascular health (obesity, diabetes, hypertension) was the quantifiable difference but the authors also included vague factors like ‘prenatal care’ and ‘education’ – which are all self-reported, and how higher education […]